Podcasts about Moderna

────────────────────────────────────────[00:02:23]Moderna Launching an mRNA Cancer Vaccine — for Patients Who Already Have Metastatic CancerThe shot caused the cancer explosion; now programming immune-compromised patients to produce tumor proteins; control group gets a different mRNA — no placebo.────────────────────────────────────────[00:10:05]Scientists Warn Moderna's mRNA Cancer Vaccine May Itself Cause Tumor GrowthJessica Rose: undisclosed antigens prevent independent safety assessment; Dr. Hoecker: counterintuitive to promote a therapy that causes cancer; FDA will approve it anyway.────────────────────────────────────────[00:34:38]Whistleblower Doctor: Booster Interval Timed to Hit White Blood Cell Production While DownFirst dose cuts production by 50%; second drops it to 25%; booster carries 81 strands of foreign bacteria the weakened immune system cannot fight.────────────────────────────────────────[00:38:48]Acosta Gave Epstein a Sweetheart Deal Because He Was Told Epstein Was Intelligence — Ken Starr Then Became His Defense AttorneyThe same Starr who gave Clinton a pass became Epstein's lawyer; a victim who refused to speak was forced forward when DOJ published her name.────────────────────────────────────────[00:40:32]Trump Sent Ivanka as a Teenager to Brunel — Modeling Agent Later Convicted of Rape and PedophiliaBrunel trafficked women into debt bondage for Epstein; the Uzbek woman now speaking out was one of his victims; Brunel died in prison in 2022.────────────────────────────────────────[01:14:55]China Cut Oil Consumption to Prevent a Global Depression — Trump Appears to Be Trying to Create OneChinese foreign minister: the Strait was open before the war; US-Israel operations created the crisis; China offset 5% of the 20% lost by cutting its consumption.────────────────────────────────────────[01:21:11]After the Iran War, Both Sides Have Revealed Their Limits — Next Conflict Requires a Domestic TriggerUS and Israel cannot change Tehran by force; Iran cannot inflict critical damage; both will prepare for a conflict requiring something to happen on American soil.────────────────────────────────────────[01:25:07]Hegseth Asks Congress for $1.5 Trillion for a War Trump Already Declared WonSenator to Hegseth: unlimited bomb money while cutting food, healthcare, and farm support; Palmer Luckey is building autonomous Terminator drones with Thiel's money.────────────────────────────────────────[01:52:30]The Covenant With Moses Was Conditional — Israel Broke It and God Destroyed the Nation ForeverPalestine today is a devilish counterfeit; the Old Testament testifies of Christ, not an ethnic group or political state — fundamental error of Christian Zionism.────────────────────────────────────────[01:55:08]Trump Contradicts Himself in the Same Sentence — Desperate to Meet Iran, But Not ReadyIran's missiles change speed mid-flight defeating every US defense system; Trump blamed Jordan attack on Jordanians. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

────────────────────────────────────────[00:02:23]Moderna Launching an mRNA Cancer Vaccine — for Patients Who Already Have Metastatic CancerThe shot caused the cancer explosion; now programming immune-compromised patients to produce tumor proteins; control group gets a different mRNA — no placebo.────────────────────────────────────────[00:10:05]Scientists Warn Moderna's mRNA Cancer Vaccine May Itself Cause Tumor GrowthJessica Rose: undisclosed antigens prevent independent safety assessment; Dr. Hoecker: counterintuitive to promote a therapy that causes cancer; FDA will approve it anyway.────────────────────────────────────────[00:34:38]Whistleblower Doctor: Booster Interval Timed to Hit White Blood Cell Production While DownFirst dose cuts production by 50%; second drops it to 25%; booster carries 81 strands of foreign bacteria the weakened immune system cannot fight.────────────────────────────────────────[00:38:48]Acosta Gave Epstein a Sweetheart Deal Because He Was Told Epstein Was Intelligence — Ken Starr Then Became His Defense AttorneyThe same Starr who gave Clinton a pass became Epstein's lawyer; a victim who refused to speak was forced forward when DOJ published her name.────────────────────────────────────────[00:40:32]Trump Sent Ivanka as a Teenager to Brunel — Modeling Agent Later Convicted of Rape and PedophiliaBrunel trafficked women into debt bondage for Epstein; the Uzbek woman now speaking out was one of his victims; Brunel died in prison in 2022.────────────────────────────────────────[01:14:55]China Cut Oil Consumption to Prevent a Global Depression — Trump Appears to Be Trying to Create OneChinese foreign minister: the Strait was open before the war; US-Israel operations created the crisis; China offset 5% of the 20% lost by cutting its consumption.────────────────────────────────────────[01:21:11]After the Iran War, Both Sides Have Revealed Their Limits — Next Conflict Requires a Domestic TriggerUS and Israel cannot change Tehran by force; Iran cannot inflict critical damage; both will prepare for a conflict requiring something to happen on American soil.────────────────────────────────────────[01:25:07]Hegseth Asks Congress for $1.5 Trillion for a War Trump Already Declared WonSenator to Hegseth: unlimited bomb money while cutting food, healthcare, and farm support; Palmer Luckey is building autonomous Terminator drones with Thiel's money.────────────────────────────────────────[01:52:30]The Covenant With Moses Was Conditional — Israel Broke It and God Destroyed the Nation ForeverPalestine today is a devilish counterfeit; the Old Testament testifies of Christ, not an ethnic group or political state — fundamental error of Christian Zionism.────────────────────────────────────────[01:55:08]Trump Contradicts Himself in the Same Sentence — Desperate to Meet Iran, But Not ReadyIran's missiles change speed mid-flight defeating every US defense system; Trump blamed Jordan attack on Jordanians. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Episode 2860 - In this episode, Ted and Austin Broer connect Moderna's RNA cancer shot trial dangers, COVID vaccine memory issues and hospital whistleblower claims, acai berry antioxidant benefits, Berberine's blood sugar and body fat management superiority, the trades career opportunity versus student loan default crisis, EV market collapse and hybrid technology promise, and the Andrew and Tate arrest for dating scams into a broadcast that delivers both urgent health warnings and sharp economic and cultural commentary.

Te invitamos a escucharnos todos los viernes en punto de las 18:00hrs. En compañía de Jorge Escamilla H. presentando su programa La sociedad Moderna- PPR mitos y realidades Compártenos tus comentarios y síguenos en nuestras redes sociales. Proyecto Radio MX, con Sentido Social

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

Le prime pagine dei principali quotidiani nazionali commentate in rassegna stampa da Davide Giacalone. I risultati degli Invalsi, lo stop di Mattarella a Nordio per la grazia a Roggero, RTL 102.5 e SAE per una nuova sinergia editoriale. Spazio Donna Moderna. Le vacanze servono per ricaricarsi. Ma siamo davvero in grado di staccare la spina e renderle efficaci? Scopriamolo con un test. In diretta Liliana Di Donato di Donna Moderna. I dati Invalsi misurano le competenze di base (italiano, matematica e inglese) di oltre 2 milioni e mezzo di studenti in Italia. I risultati mostrano un calo nazionale degli apprendimenti e divari territoriali tra Nord e Sud. Peggiora la primaria, disastro in matematica, migliorano le superiori. Ne abbiamo parlato con il prof. Antonio Fundaroò, docente e redattore di Orizzonte Scuola. La sentenza del crollo del ponte Morandi a Genova, avvenuto nell'agosto del 2018. In diretta Silvia Salis, sindaca di Genova. Spazio Mondiali. In collegamento la nostra squadra di Cronisti Mondiali. Con ognuno di loro abbiamo approfondito un tema. Domenica la finale tra Argentina e Spagna. Come sono arrivate le due squadre a questo traguardo? Paolo Pacchioni. Il confronto tra Messi e Yamal. C'è una bella storia dietro. Nicolò Pompei. In Italia si discute per la scelta del nuovo commissario tecnico della Nazionale. com'è la situazione? Lo abbiamo chiesto a Tommaso Angelini. I fatti di attualità commentati dal direttore dell'Ansa, Luigi Contu. All'interno di Non Stop News, con Barbara Sala, Ludovica Marafini e Dario Vanacore.

Oskar, Jacob och Madelene ger sig ut på roadtrip i Västsverige för att hitta skruvade resmål som är värda en omväg. I veckans avsnitt letar de upp en modern hällristning strax söder om Göteborg. Vad skulle man själv vilja förmedla till framtiden, hur kommer 3026-människorna tolka ett Jas-plan och vad är egentligen en samlagssten? Häng med oss ut i Sommarsverige!Vill du ta del av fler skruvade resmål? Besök magasinetfilter.se för fler oväntade tips i hela Sverige. Podden görs av Magasinet Filters redaktion. Prenumerera på Filter här.

Deputāti komisijā atbalsta ieceri veidot īpašu fondu Latvijas austrumu teritorijas attīstībai; jālemj būs Saeimai. Joprojām asas diskusijas par vēja parka ieceri Augšdaugavas novadā. Lietuva un Polija brīdina par iespējamiem Krievijas provokāciju scenārijiem. Modernas un drošas telpas, plašākas ārstniecības, aprūpes un diagnostikas iespējas – tas tiek solīts jaunā Plaušu veselības un infekcijas slimību korpusa pacientiem Rīgas Austrumu klīniskajā universitātes slimnīcā. Ir sagatavoti priekšlikumi informācijas un komunikāciju tehnoloģiju iepirkumiem. Priekšlikumus izstrādājusi Viedās administrācijas un reģionālās attīstības ministrija kopā ar IUB un Finanšu ministriju, atsaucoties uz premjera rezolūciju.

Abrimos La Ventana de los libros para entrevistar a la escritora Mar Horno. Vuelven el concurso de Relatos con banda sonora con Miguel Ángel Marcos, profesor de los cursos del Área de Creación Musical de Escuela de Escritores, músico, productor y compositor,  que será el encargado de convertir el microrrelato ganador del concurso en una canción que se estrenará el próximo lunes 31 de agosto; y Beatriz Díaz Rodríguez, ganadora del concurso de año pasado.  Ana Valtierra vuelve con su sección La casa azul y Pilar de Francisco se encarga de cerrar este tramo. 

Grötiga terroristtankar, banbrytande filosofi och viktiga litterära författarskap. Allt rymdes hos Bo Cavefors förlag. Det får en av fundera över dagens intellektuella klimat, säger Tor Billgren. Lyssna på alla avsnitt i Sveriges Radios app. ESSÄ: Detta är en text där skribenten reflekterar över ett ämne eller ett verk. Åsikter som uttrycks är skribentens egna. Först sänd 2018-06-14.”RAF: texter”, som publicerades på Bo Cavefors förlag i oktober 1977 måste vara en av bokhistoriens mest vältajmade utgivningar. Det är en 520-sidig antologi med texter av aktivister inom den västtyska terrorgruppen Röda Arméfraktionen, RAF.Cavefors berättar om publiceringen i Malmökonstnären Lena Mattssons filminstallation ”I betraktarens öga”, som visades på Moderna Museet i Malmö 2014. Förutom den svenska boken, gav han också ut en utgåva på tyska, eftersom inget tyskt förlag vågade göra det. För att böckerna inte skulle fastna i tullen, fabricerade han ett fejkomslag: ”Kärlek med förhinder” stod det på framsidan av ett stort antal av de tyska böckerna.Cavefors hade starka drivkrafter, både politiska och litterära. I Lena Mattssons intervjufilm kallar han sig ”kulturell onanist”.Det som gör boken så vältajmad, är att det var just i oktober 1977, som palestinska PFLP kapade ett Lufthansaplan med kravet att ett antal fängslade RAF-ledare skulle friges.I fem dagar irrade planet runt i Mellanöstern med fem besättningsmedlemmar och 86 passagerare som gisslan, sju av dem barn. Tidigt på morgonen den 17 oktober kunde planet slutligen landa i Mogadishu, Somalia. Det stormades av tysk specialpolis, och gisslan fritogs.Följande morgon hittades RAF:s fängslade ledare, Andreas Baader, Gudrun Ensslin och Jan-Carl Raspe döda i sina fängelseceller i vad som förmodligen var ett koordinerat självmord.I samma veva lägger alltså Bo Cavefors ”RAF: texter” på bokhandelsdiskarna.Det var förstås också en mycket kontroversiell utgivning. RAF hade vid det laget mördat 16 personer i sina olika aktioner, varav två i Stockholm under ockupationen av Västtyska ambassaden 1975.Och våren 1977 hade SÄPO slagit till mot en RAF-trogen terrorcell i Sverige som planerade att kidnappa före detta ministern Anna-Greta Leijon i utpressningssyfte. Så hösten 1977 visste alla vad RAF var. Bo Cavefors hade en särskild näsa för det som låg i tiden.Han startade sitt bokförlag 1959, men det är först 2018 som historien om förlaget berättas utförligt i bokform. Det är bokhistorikern Ragni Svensson som gör det i sin doktorsavhandling ”Cavefors – Förlagsprofil och mediala mytbilder i det svenska litteratursamhället 1959–1982”.Första året gav den då 27-årige förläggaren ut nio titlar från sitt föräldrahem i Limhamn, bland annat ”Sju algeriska studenters vittnesmål om tortyren i Frankrike” och tre böcker av den mycket kontroversielle poeten Ezra Pound.Stig Claesson sökte sig tidigt till förlaget, liksom en ung Lars Norén. Honom refuserade dock Cavefors, tre gånger på tre år.Förlaget fick snabbt en vänsterpolitisk profil. Ragni Svensson noterar att utgivningen kom att ”spegla eller rentav föregå den väg som den svenska vänsterrörelsen kom att ta framåt slutet av 1960-talet”.Cavefors gav ut Mao Tse-tung, Rosa Luxemburg, Antonio Gramsci, Marx, Stalin, Lenin och Nordkoreas diktator Kim Il Sung.Det kom tjogtals med titlar som ”En socialistisk kultursyn”, ”Marxismens politiska ekonomi” och ”Kulturrevolutionen vid Kinas universitet”.Han introducerade tänkare och filosofer som Roland Barthes och Michel Foucault. Peter Weiss knöts tidigt till förlaget, och 1975 gav Cavefors ut den nigerianske författaren Wole Soyinka, 11 år innan han fick Nobelpriset.Det är inte dåligt för vad som länge var ett enmansförlag. Men Cavefors hade starka drivkrafter, både politiska och litterära. I Lena Mattssons intervjufilm kallar han sig ”kulturell onanist”.Att läsa om Bo Cavefors skapar funderingar om intellektuell takhöjd och diskussionsklimat nu och då. Vill man få en överblick över vidden av utgivningen kan man ta till en annan bok från 2018: ”BOC – en bok om Bo Cavefors Bokförlag”, som innehåller en komplett bibliografi.De Caveforsböcker som jag själv har starkast kontakt med är Salvador Dalís självbiografi, som tidigt väckte mitt intresse för konst. En annan är William Burroughs ”Den nakna lunchen”, som Cavefors tog till Sverige 1978. Jag hittade den på en loppmarknad i Simrishamn 1996 och läste den på ett kvavt tåg samma sommar som jag skulle rycka in i Flottan. Boken var osprättad, så jag satt med min morakniv och skar. Sida efter sida sköljde bokens febriga och erotiska hallucinationer över mig.Förlaget gick under i det som kom att kallas Caveforsaffären; en stormig process som spelades upp kring 1980. Bo Cavefors hade vunnit en upphandling från Kulturrådet om att ge ut Strindbergs samlade verk i ny utgåva. Men mitt under förberedelsearbetet drogs beslutet tillbaka.Officiellt på grund av brister i upphandlingsförfarandet, men i den debatt som följde menade Cavefors försvarare inom kulturvärlden att det var hans kontroversiella utgivning som var det egentliga skälet. Han var för obekväm, för besvärlig.Snart kom också anklagelser om ekonomisk brottslighet. Han satt häktad i polishuset i Lund i nio dagar, men frikändes sedan på 10 av 11 åtalspunkter. Förlaget gick i konkurs och i början av 1981 såldes det enorma boklagret i en legendarisk utförsäljning. Det är förmodligen från denna som min osprättade Burroughsbok härstammar.Att läsa om Bo Cavefors skapar funderingar om intellektuell takhöjd och diskussionsklimat nu och då. Hade utgivningarna av till exempel Ezra Pound, Stalin och den svenske fascistledaren Per Engdahl, vars memoarer Cavefors gav ut 1979, kunnat stå emot dagens sociala medierdrev och polariserade åsiktsjournalistik?Hade ett etablerat förlag idag kunnat ge ut visdomsord från Islamiska Statens teologer, eller Anders Behring Breiviks manifest?Bo Cavefors har motiverat utgivningen av RAF-boken med att det rörde sig om ”viktiga dokument för den tiden”.Att publicera något måste inte betyda att man ställer sig bakom det. Det finns en historisk och vetenskaplig poäng med att tillgängliggöra material för den tänkande allmänheten, även av kontroversiell, oetisk och korkad natur.Kanske är den här nakenheten exhibitionism, precis som det kan vara exhibitionism att ge ut böcker.Efter tiden med förlaget har Bo Cavefors i hög grad fortsatt med sin kulturella onani. Han har skrivit böcker och gett ut tidskrifter, men också samarbetat med olika konstnärer. I Lena Mattssons installation som visades på Moderna i Malmö, ingår förutom intervjufilmen, bland annat också en liten projektion av en naken Cavefors från en pjäs som han satte upp i Malmö 2005.Den här nakenheten återkommer i flera konstnärliga samarbeten, till exempel med Martin Bladh på Fylkingen i Stockholm 2009, och med Leif Holmstrand. Boken ”Ett rum på tredje våningen” består av textflöde och bilder, där en åldrad Cavefors poserar i olika sexuella situationer, inte sällan insnärjd i Holmstrands virkade girlanger.Kanske är den här nakenheten exhibitionism, precis som det kan vara exhibitionism att ge ut böcker: att torgföra sina åsikter och posera med vad man tycker är viktigt.Kanske är nakenheten provokation, precis som det kan vara provokation att ge ut Stalin eller ett tjockt manifest med ”grötiga terroristtankar och livsfarlig våldsromantik”, som en av recensenterna beskrev RAF-boken.För 40–50 år sedan yttrade sig denna inskränkthet genom upprop om moralisk resning, idag genom krav på trygga rum och triggervarningar.Men det är ett ytligt sätt att se på saken. Jag ser snarare nakenheten som ett verktyg för att ifrågasätta kroppsideal och avslöja fördomar, precis som utmanande bokpubliceringar kan avslöja inskränkthet och en subjektiv och godtycklig syn på yttrandefrihet.För 40–50 år sedan yttrade sig denna inskränkthet genom upprop om moralisk resning, idag genom krav på trygga rum och triggervarningar.Ett samhälle behöver sina obekväma och besvärliga personer. Det är de som lockar den indignerade flocken att demonstrera var toleransens gränser går.Tor Billgren, frilansjournalist LitteraturRagni Svensson: Cavefors – förlagsprofil och mediala mytbilder i det svenska litteratursamhället 1959–1982. Ellerströms, 2018.Anna-Lina Brunell, Ragni Svensson, Jonas Ellerström, Bo Cavefors: BOC – en bok om Bo Cavefors förlag. Tragus förlag, 2018.Leif Holmstrand & Bo Cavefors: ”Ett rum på tredje våningen” (Holmstrand Böcker, 2015)Martin Bladh & Bo I. Cavefors: ”Qualis artifex perero” (Styx, 2013) FilmerLena Mattsson: ”In the eye of the beholder”Lena Mattsson: ”Den kulturelle onanisten”

Le prime pagine dei principali quotidiani nazionali commentate in rassegna stampa da Davide Giacalone. Le bombe su Hormuz, il caso di Luigia Fortunato che per la procura no è femminicidio, Conte e la linea sul riarmo, i social sotto accusa. Spazio Donna Moderna. Levacanze da single. Ne abbiamo parlato in diretta con Myriam Defilippi, di Donna Moderna. Spazio Moto GP. Questo weekend si correva in Germania. Ill punto con il nostro inviato speciale, Max Biaggi. Spazio Mondiali. In collegamento la nostra squadra di Cronisti Mondiali. Con ognuno di loro abbiamo approfondito un tema. Ieri e oggi niente partite; si riparte domani con la prima semifinale Francia-Spagna, poi mercoledì Inghilterra-Argentina. Con Nicolò Pompei abbiamo sentito come stanno le quattro Nazionali rimaste in corsa. È iniziata una settimana cruciale anche per il futuro della Nazionale italiana. Cosa dobbiamo aspettarci? Lo abbiamo chiesto a Paolo Pacchioni. Il direttore regionale dei vigili del fuoco Piemonte, Alessandro Paola, è intervenuto in diretta per parlarci della situazione incedi in Italia. Il Parlamento Europeo ha recentemente approvato nuove regole che riguardano i diritti dei passeggeri che viaggiano in aereo. Alcuni cambiamenti sono significativi. Il punto con Leonard Berberi, del Corriere della Sera. Spazio tennis. Ieri a Wimbledon, la finale tra Sinner E Zverev. Abbiamo fatto il punto con Ivan Ljubicic, ex tennista di grande successo, oggi allenatore. L'attualità economica, commentata dal prof. Carlo Cottarelli, economista. All'interno di Non Stop News, con Giusi Legrenzi, Lucrezia Bernardo, Enrico Galletti e Massimo Lo Nigro.

Antes de la Revolución Industrial, la medicina se había estancado en un estado de desarrollo similar al de la Edad Media. Proliferaban las enfermedades, y el promedio de vida apenas alcanzaba los 36 años. En este episodio relatamos la asombrosa historia de los pioneros de la razón y de la ciencia que desafiaron al viejo orden. James Lind dirigió el primer ensayo clínico, el cual confirmó que era posible prevenir el escorbuto y salvar las vidas de miles de marineros utilizando naranjas y limones. Edward Jenner, un médico preocupado por las hermosas lecheras, utilizó su capacidad de observación y el pensamiento lateral para encontrar una vacuna contra la viruela. El doctor René Laennec era terriblemente tímido. No soportaba la idea de tener que acercar la oreja a los pechos de sus pacientes femeninas. Por eso inventó el estetoscopio, un instrumento clave a la hora de diagnosticar que hoy se ha convertido en un icono de la profesión médica

Te invitamos a escucharnos todos los viernes en punto de las 18:00hrs. En compañía de Jorge Escamilla H. presentando su programa La sociedad Moderna- Verdades incómodas del Mercado de Sonora Compártenos tus comentarios y síguenos en nuestras redes sociales. Proyecto Radio MX, con Sentido Social

Noubar Afeyan helped bring one of medicine's biggest breakthroughs to the world through Moderna's Covid-19 vaccine. In this episode, he explains why what looked like an overnight success was actually decades in the making.Presenter: Will Bain Producers: Barbara George and David Cann Researcher: Aleeza Siddiq

La cancionera mexicana Avelina Landín con el trío 'Tamaulipeco', desde los estudios de la Radio Cadena Suaritos, nos recuerda el esplendor de La Habana como plaza artística donde numerosas figuras extranjeras conquistaron el éxito. Y de tierras aztecas también llegaron los charros con su vestuario típico, los mariachis y, por supuesto, aquel repertorio popularizado en cientos de películas. Tito Guízar, finalizando los años 30, fue el primero en poner de moda en las pantallas cinematográficas la figura del "charro cantor". Las antenas de la CMQ nos devuelven, en vivo y en directo, el arte de aquellos astros del cine de oro azteca. A continuación Jorge Negrete con el trío "Calaveras" y Pedro Infante con el mariachi "Vargas". Apoyo de la Orquesta CMQ bajo la conducción del maestro Enrique González Mánticci. Unos minutos más recordando a estos valiosos artistas que llegaron a La Habana en busca de reconocimiento y éxito. El Trío "Janitzio" se presentó en la Habana de marzo de 1945. Emisiones históricas de la Mil Diez. Graciela Pérez durante décadas identificó, junto a su hermano Machito, la sonoridad de los "Afrocubans". Sin dudas una de las bandas más progresivas del Nueva York de comienzos de los años 40. Bajo la guía musical de Mario Bauzá, sus formidables cualidades interpretativas, acompañadas de un notable desenfado escénico, le concedieron el éxito. Falleció en Nueva York, la ciudad de sus grandes éxitos, el 7 de abril de 2010, a los 95 años. Nos acercamos brevemente al álbum 'Con el permiso de Bola', producido por Warner Music de México en 2006 y protagonizado por Pancho Céspedes y Gonzalo Rubalcaba. Así celebramos el premio a la Excelencia Musical con que la Academia de los Latin Grammy ha distinguido la trayectoria artística de Pancho Céspedes. Merecido reconocimiento al maestro quien, a lo largo de su carrera, ha dejado huella en los escenarios del mundo en su doble condición de compositor e intérprete. Muchas felicidades le deseamos al maestro Pancho Céspedes. La era de los cuartetos vocales comenzó a cobrar fuerza en Cuba, a mediados de los años 40, de la mano de relevantes pianistas como Isolina Carrillo, Orlando de la Rosa, Facundo Rivero, y Bobby Collazo, entre otros. Para la década siguiente el auge de clubes y cabarets favoreció la aparición de otras formaciones dirigidas por otros pianistas como Mario Fernández Porta y Carlos Faxas. Sin embargo la más sobresaliente resultó ser el cuarteto organizado por Aida Diestro en 1952. Con una marcada presencia en esos espacios, así como en los directos de radio y televisión, el cuarteto D'Aida iluminó los escenarios con su espléndido empaste vocal y armónico en función de un selecto y variado repertorio. En las pistas de emblemáticos sitios de la noche habanera como "Tropicana" y "Sans Souci" desarrolló magníficas temporadas. En el 96 aniversario de su natalicio recordamos a Tata Güines. Auténtico orfebre del sabor, siempre reconoció el arte de los percusionistas que le antecedieron, entre ellos Carlos Patato Valdés a quien invariablemente señaló como el primero en haber utilizado dos tumbadoras con afinación. Tata, finalizando los años 50, ya era elemento a tener en cuenta en el ambiente de las descargas, los shows de radio y televisión, así como las numerosas producciones que, casi a diario, generaba una industria discografica independiente y en franco desarrollo. En este último apartado tuvieron absoluta importancia en su carrera las llamadas "descargas en miniatura" de Cachao López y el debut del Quinteto de Música Moderna con el pianista Frank Emilio Flynn a la cabeza. Tata Güines en la memoria.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wave of exciting advancements and strategic movements shaping the landscape of this ever-evolving industry. Starting with a significant breakthrough in cell therapy, the FDA has granted approval to Orca Bio's Tregzi, a novel treatment aimed at preventing graft-versus-host disease (GVHD) in blood cancer patients undergoing allogeneic transplants. This approval emphasizes the potential of regulatory T cells in mitigating the severe complications that often accompany such transplants. The success of Tregzi not only marks a pivotal moment for cell therapy but also heralds a new era in transplant medicine where cellular therapies can significantly improve patient outcomes by reducing GVHD incidence. In other strategic moves, Ipsen's acquisition of Memo Therapeutics for up to $796 million highlights the industry's focus on addressing unmet needs in transplant medicine. Memo's work on monoclonal antibodies targeting the BK virus—a significant threat to kidney transplant patients—reflects a growing trend towards personalized medicine and targeted biologics. This acquisition is poised to bring much-needed therapeutic interventions to market, underscoring the sector's commitment to innovative solutions. Meanwhile, Anthropic is making waves with the introduction of Claude Science AI Workbench, accompanied by an internal drug discovery program aimed at neglected diseases. This initiative underscores the transformative role of artificial intelligence in drug discovery, particularly in areas previously overlooked due to limited commercial incentives. By accelerating the identification and development of novel therapeutics, AI-driven platforms promise breakthroughs in treating rare and neglected diseases. In clinical trial news, Abivax has reported promising Phase 3 safety data for obefazimod, a miR-124 enhancer targeting ulcerative colitis. By alleviating previous cancer-related concerns, obefazimod stands out as a potential small molecule oral therapy for autoimmune conditions. This advancement demonstrates ongoing innovation in small molecule therapeutics designed to modulate immune responses, expanding treatment options for ulcerative colitis patients. On the financial front, several companies are bolstering their pipelines through significant funding efforts. Alvotech has secured a $75 million term loan to enhance its biosimilar pipeline, reflecting the increasing importance of cost-effective biologic alternatives. AB Science has raised approximately $2.62 million focusing on oncology and rare diseases like acute myeloid leukemia (AML) and amyotrophic lateral sclerosis (ALS). Additionally, Flare Therapeutics' $85 million Series C round emphasizes precision medicine approaches targeting transcription factors, illustrating the industry's dedication to precision medicine. Regulatory landscapes are also shifting with Sarepta Therapeutics' FDA acceptance for full approval bids on Amondys 45 and Vyondys 53 despite confirmatory trial challenges. These therapies leverage exon skipping technology for Duchenne muscular dystrophy treatment, highlighting the intricate balance between accelerated approvals and robust clinical evidence requirements. In mergers and acquisitions news, Kimball Electronics' acquisition of Helvoet Polymer Technologies expands their drug delivery systems capabilities across Europe and India. This strategic alignment reflects broader industry trends towards integrated service offerings and global expansion efforts. Regulatory challenges continue with leadership changes at the FDA as Vijay Kumar steps down amid ongoing turbulence within gene and cell therapy sectors. Additionally, Angitia Biopharmaceuticals' termination of its Phase 3 trial for its BMP-6 candidate illustrates inherent risks and strategic pivots often necessary in drug development. Turning our focus globally, China's approval of its first CAR-T therapy for solid tumors signals a pivotal moment in oncology. This milestone could spur similar advancements worldwide, particularly drawing interest on when such treatments might receive approval in other regions like the United States. Moderna's expansion into in vivo CAR-T therapies for autoimmune diseases further marks a strategic divergence from traditional approaches, aiming to create off-the-shelf solutions that redefine treatment paradigms. Gene therapy continues to gain traction as Uniqure navigates regulatory reversals from the FDA regarding its Huntington's disease gene therapy filing for accelerated approval. This development hints at a broader shift within regulatory bodies towards fostering innovation in rare disease treatments under new leadership directives. Industry-wide trends also reveal a notable shift towards automation in cell therapy production led by companies like Cellares and Ori. This reflects growing demands for scalable manufacturing processes that enhance production capabilities while reducing costs. Overall, these developments illustrate a dynamic landscape where scientific innovations, strategic partnerships, regulatory adjustments, and technological integrations drive progress across various medical fields. As these sectors evolve, they hold vast potential for transforming patient care through groundbreaking therapeutic options and improved healthcare delivery systems worldwide.Support the show

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über Biotech-Gewinner, die lukrative Nagarro-Offerte und das Halbjahres-Orakel. Außerdem geht es um GameStop, eBay, Moderna, Biogen, Apellis Pharmaceuticals, SpaceX, JPMorgan, Nasdaq, Nagarro, Persistent Systems, FactSet, General Mills, Constellation Brands, Tesla, CrowdStrike, AeroVironment, Apple, Microsoft, Amazon, Nvidia, Alphabet, Meta, Micron, BYD, Geely, Volkswagen. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Diese Folge enthält Werbung für Smartbroker+. Depot eröffnen, 30 € ETF als Bonus sichern und aus tausenden ETFs wählen. Smartbroker+ macht Investieren einfach. Alle Informationen gibt es unter: https://get.smartbrokerplus.de/triple-aaa-podcast2/ Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the landscape of this dynamic industry. Replimune has made headlines with the resubmission of its oncolytic virus-based immunotherapy, RP1, to the U.S. Food and Drug Administration for treating advanced melanoma. The FDA's acceptance after two prior rejections is significant, suggesting a shifting regulatory landscape that could favor innovative cancer therapies like oncolytic viruses. These therapies represent a novel approach to engage the immune system in targeting tumors, and if RP1 gains approval, it may open doors for similar treatments, potentially offering new hope for melanoma patients. On the regulatory side, Amgen has encountered challenges with Tavneos after losing European Union endorsement due to data integrity issues. This serves as a stark reminder of the critical importance of maintaining stringent data management throughout drug development. With an FDA hearing on the horizon, the implications are far-reaching, emphasizing increased scrutiny from regulatory bodies worldwide. This scenario could lead to more rigorous guidelines governing data practices in the future. The European Commission's approval of Henlius' Hetronifly as a first-line treatment for squamous non-small cell lung cancer marks a milestone in cancer immunotherapy. This approval highlights the ongoing efforts to improve patient outcomes through innovative PD-1 inhibitor-based combination therapies, showcasing progress in the fight against one of the most challenging forms of cancer. Epicrispr Biotechnologies brings promising news from its phase 1/2 trial of EPI-321, a gene therapy for facioscapulohumeral muscular dystrophy. The trial's success in enhancing muscle function through epigenetic silencing underscores significant advancements in gene therapy applications for neurological disorders. Similarly, Abbisko Therapeutics' phase 2 trial reports a 90% objective response rate using FGFR2/3 and PD-L1 inhibitors for gastric cancer, demonstrating the potential of targeted small molecule therapies in oncology. In financial developments, Definium Therapeutics and Ligachem Biosciences have made substantial funding strides to bolster their drug development pipelines. Definium's $805 million raise aims to advance psychiatric and neurological treatments, while Ligachem's funding will enhance its antibody-drug conjugate platforms. These investments reflect strong investor confidence in next-generation therapeutic platforms and underscore innovative financing strategies crucial for sustaining research and development efforts. Bayer's recent legal victory at the Supreme Court overturning a $1.25 million verdict related to its Roundup product is another focal point. This ruling not only positively impacts Bayer's financial standing but also highlights the complexities surrounding product liability cases within pharmaceuticals and agrochemicals. Strategically, Moderna has unveiled an ambitious R&D roadmap aiming for break-even by 2028 with over seven new products on the horizon. By focusing on mRNA vaccines for oncology and rare diseases, Moderna continues to leverage its technology beyond COVID-19 applications, potentially transforming treatment paradigms across various therapeutic areas. Shifting focus to industry trends, Sanofi finds itself under investigation by the European Commission for antitrust violations linked to its flu vaccine marketing practices. This situation underscores growing scrutiny over competitive practices within the pharmaceutical sector and could influence regulatory compliance strategies across global markets. In technological advancements, Eli Lilly is employing artificial intelligence to raise awareness about Alzheimer's disease through creative engagements like a European radio show road trip. These initiatives reflect an industry-wide shift towards technology-driven marketing strategies aimed at personalizing patient interactions. Lastly, Merck KGaA's $11 billion acquisition of Bio-Techne exemplifies a strategic move to enhance capabilities in immune cell therapy production. This deal underscores the growing importance of manufacturing innovations in bringing advanced therapies to market and highlights strategic collaborations increasingly seen across the sector. The landscape is further defined by significant scientific breakthroughs such as Revolution Medicines' development of a second RAS blocker, showing improved chemotherapy responses in pancreatic cancer patients. These advancements underscore the need for continued investment in targeted therapeutics research as they promise better patient outcomes and highlight ongoing innovation within oncology. As these developments unfold, they reflect an industry poised for transformation amid evolving scientific, regulatory, and market dynamics aimed at improving patient care globally. With these insights into current trends and future directions, it's clear that the pharmaceutical and biotech sectors are navigating a period rich with potential for groundbreaking advancements that will shape healthcare outcomes worldwide.Support the show

MAHA feels like a distant memory as we are not seeing any progress to speak of. The FDA voted 9-0 to approve Moderna's Flu vaccine this fall and for the first time ever it will be mRNA. We know the risks with mRNA having just seen that technology with Covid-19. Hit subscribe and never miss a show!

While Elsevier's most recent Clinician of the Future Report shows increasing adoption of artificial intelligence tools among physicians and nurses, and optimism that they will improve quality of care in the future, a majority raised concerns about trust and reliability. To increase the level of trust, 60% said transparent citations of evidence-based and peer-reviewed research will be key. How to provide that transparency is our focus today as Raise the Line host Lindsey Smith welcomes Elsevier colleagues Rhett Alden and Raman Kaur to guide us through the complexities involved, including the concept of traceability and what role it plays in how AI tools such as Elsevier's ClinicalKey AI are built and deployed.  “Traceability changes the confidence that a clinician has in an AI tool so that they aren't trusting the AI, they're trusting the underlying evidence they're consuming from the AI-assisted platform,” says Raman, who brings years of experience as a primary care practitioner to her work.  It's also important, Rhett adds, to provide additional information, pulled from both the clinician's query and the patient's medical record, to inform clinical thinking. “ClinicalKey AI can be more than a response engine by establishing a larger context to provide a more precise answer for that individual patient.” In this thought-provoking discussion, these experts also provide insights on: Mitigating bias in AI results; Using AI responsibly with sustainability in mind; What type of clinician will benefit most from AI Mentioned in this episode: ClinicalKey AI Clinician of the Future Report If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic shifts that are shaping the future of healthcare. In a remarkable development from China, Carsgen has achieved approval for the world's first CAR-T therapy targeting solid tumors. This therapy focuses on Claudin18.2, marking an unprecedented expansion of CAR-T applications beyond hematologic malignancies. The significance of this breakthrough cannot be overstated, as it opens new avenues for treating cancers resistant to traditional therapies, offering hope to patients worldwide. Meanwhile, in regulatory news, the U.S. is closely examining Germany's proposed drug spending reforms due to concerns over "persistent underpayment" for new medications. This scrutiny highlights the complexities of international pharmaceutical pricing and could have profound implications for drug accessibility and pricing strategies across Europe. Sanofi is undergoing transformative changes under CEO Belen Garijo's leadership. The departure of R&D chief Houman Ashrafian and the appointment of Paulo Fontoura, known for his work at Roche, signal a strategic pivot to rejuvenate Sanofi's research and development pipeline. This move aims to address challenges within Sanofi's pipeline and inject new energy into its R&D initiatives. Reflecting broader industry trends, Eli Lilly is reevaluating its marketing strategies amid increasing emphasis on pharmaceuticals in mainstream health discussions. This introspection aligns with efforts across big pharma to enhance corporate image alongside product portfolios. The Federal Trade Commission recently mandated that Aurobindo divest four drugs as part of its $250 million acquisition of Lannett, addressing antitrust concerns and ensuring competitive balance in the generics market. Pfizer has made headlines with a rapid $10 billion oncology deal with Innovent Biologics. This collaboration underscores an industry trend towards swift, large-scale partnerships aimed at expanding global pharmaceutical ambitions. The deal's finalization in under five months illustrates the increasing pace at which such collaborations are being forged. Moderna continues to expand its mRNA capabilities beyond COVID-19 with unanimous FDA advisory committee support for its influenza vaccine candidate. This advancement signifies Moderna's strategic entry into broader vaccine markets, leveraging its mRNA platform to potentially transform vaccine development for seasonal influenza. AbbVie's acquisition of Apogee Therapeutics for $10.9 billion marks a competitive maneuver in the dermatology space. With a promising late-phase eczema drug candidate, AbbVie positions itself against market leaders like Eli Lilly, Regeneron, and Sanofi. Definium Therapeutics has announced promising phase 3 data for its novel LSD-based treatment for depression. This development has the potential to revolutionize mental health treatment paradigms by demonstrating unprecedented efficacy in psychedelic therapeutics. In an innovative stride forward, Insilico Medicine's collaboration with SK Biopharm on an AI-driven drug discovery initiative highlights the growing reliance on artificial intelligence to accelerate drug development pipelines. Targeting neuroimmune disorders, this partnership could be valued at over $2.5 billion, exemplifying AI's transformative potential in pharmaceutical innovation. These developments collectively highlight an industry characterized by rapid scientific advancements and strategic realignments. By expanding CAR-T therapies to solid tumors and integrating AI-driven drug discovery approaches, alongside significant regulatory updates and strategic collaborations, the pharmaceutical and biotech sectors are poised for continued evolution in patient care and drug development methodologies. As we continue to witness these transformative changes across pharmaceuticals and biotechnology, it remains crucial for stakeholders to adapt swiftly and collaborate effectively. The integration of novel technologies such as mRNA platforms, gene editing advancements, and AI-driven research will undoubtedly shape future healthcare outcomes and redefine traditional approaches to medicine. Thank you for tuning into Pharma Daily. We hope you found today's insights valuable as we navigate these dynamic shifts within the pharmaceutical and biotech landscapes together. Stay informed and join us next time as we continue to explore the cutting-edge developments driving healthcare innovation forward.Support the show

Dirige y presenta: Juan Carlos Baruque Hernández Sumario del programa DANIEL GARCÍA *¿Nos espían desde las tecnologías modernas? Nuestra Web: https://mundoinsolitoradio.es Contacta: +34 687 39 80 12 - Solo WhatsApp mundoinsolitoradio@hotmail.com Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Esta semana falamos do primeiro navio a vapor a atravessar o Atlântico, em 1819, e sobre as reuniões de Cortes em Portugal, entre os séculos XIII e XIX.Sugestões da semana:1. Eve MacDonald - Cartago - O Império que desafiou Roma. Bertrand, 2026.2. Olivier Aranda, Julien Guinand, Caroline Le Mao - Atlas das Guerras: Época Moderna. Guerra & Paz, 2026.-----Obrigado aos patronos do podcast:André Silva, Bruno Figueira, Cláudio Batista, Gustavo Fonseca, Isabel Yglesias de Oliveira, Joana Figueira, NBisme, Oliver Doerfler, Sara Esteves, Sofia Carvalho;Alexandre Carvalho, Andre Oliveira, Carlos Castro, Civiforum, Lda., Cláudia Conceição, Daniel Murta, Domingos Ferreira, Francisco C, Hugo Picciochi, Jorge Filipe, José Beleza, Luís André Agostinho, Miguel Cunha, Patrícia Gomes, Pedro Almada, Pedro Alves, Pedro Ferreira, Rui Roque, Tiago Pereira, Vera Costa;Adriana Vazão, Ana Gonçalves, André Abrantes, António Farelo, António J. R. Neto, Bruno Luis, Carlos Ribeiro, Carlos Ribeiro, Carolina Batista, Catarina Ferreira, Cláudia Brandão, César, Diogo Camoes, Diogo Freitas, Francisco Castro, Fábio Videira Santos, Gn, Goncalo Castro, GusRo, Hugo Palma, Hugo Vieira, Igor Silva, Joao Godinho, Joel José Ginga, Johnniedee, Jorge Manuel, João Barbosa, João Canto, João Carlos Braga Simões, João Diamantino, João Ferreira, João Félix, João Mendes, Liam Brockey, Luis Colaço, lvlheadwrecker, Mafalda Trindade, Marcos, Miguel Brito, Miguel Gama, Miguel Gonçalves Tomé, Miguel Oliveira, Miguel Salgado, Nuno Carvalho, Nuno Esteves, Nuno Moreira, Nuno Silva, Orlando Silva, Parte Cóccix, Paulo Guerreiro, Paulo Ramirez, Paulo Ruivo, Paulo Silva, Pedro Cardoso, Pedro Oliveira, Pedro Sebastião, Ricardo Pinho, Ricardo Santos, Rodrigo Candeias, Rui Magalhães, Rui Rodrigues, Simão, Simão Ribeiro, Thomas Ferreira, Tiago Matias, Tiago Sequeira, Tomás Matos Pires, Vitor Couto, Zé Teixeira.-----Ouve e gosta do podcast?Se quiser apoiar o Falando de História, contribuindo para a sua manutenção, pode fazê-lo via Patreon: https://patreon.com/falandodehistoria-----Música: "Hidden Agenda” de Kevin MacLeod (incompetech.com); Licensed under Creative Commons: By Attribution 4.0 License, http://creativecommons.org/licenses/by/4.0.Edição de Marco António.

Cap

Cap

Episode 2838 - In this wide-ranging Friday episode, Ted and Austin Broer connect ultra-processed food cardiovascular risk research, the FDA's surprise nine-to-zero approval of Moderna's RNA flu shot with only 26% efficacy, a daily multivitamin study showing reduced biological aging, speed limiter mandates coming to American cars by 2030, Apple's price hikes tied to AI data center memory costs, and foundational supplement guidance into a broadcast that delivers both urgent health warnings and sharp institutional accountability.

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (6/19/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v79cuai","div":"rumble_v79cuai"}); Source Links (In Chronological Order): (14) CALL TO ACTIVISM on X: "This should frighten us all. REPORTER: What have you learned about not just the exercise of power but the limits on your power as a result of the conflict? TRUMP: There are no limits. REPORTER: No limits? TRUMP: No, I haven't learned that lesson yet. I know there are, but you https://t.co/oWD5JKxfAY" / X What The Hell Is Happening w/ Charlie Robinson (6/18/26) (6) TheTexasOne on X: "Blowing up drug boats saves American lives!" / X Top Pentagon Official Admits Boat Strike May Have Killed Victims of Human Trafficking (14) Drop Site on X: "⭕️ Senate threatens to freeze Hegseth's travel budget over Iran school bombing, boat strike videos Senate lawmakers are threatening to withhold 75 percent of Defense Secretary Pete Hegseth's travel budget if the Pentagon doesn't turn over more details on the deadly February https://t.co/5kK8Dg25v1" / X New Tab Animal Activists Arrested Attempting to Rescue Tortured Beagles While RFK Jr. Claims Ignorance Lawsuit Reveals "Cruel" Experiments on Kittens Continue Under Kennedy and Trump (9) The Last American Vagabond on X: "Neither side will do anything. People like Benny are the modern version of the Q psyop. They keep you feeling like you're just on the edge of massive change & disruption, all while making sure you never "counter-signal the leader" or ever actually do something. #ArrestSomeone" / X (10) The Last American Vagabond on X: "Prediction: no matter what you “reveal” no one will ever be arrested." / X (10) The Last American Vagabond on X: "This is what they mean when they say the “Epstein class”." / X (10) The Tennessee Holler on X: "This is real. A no-bid reflecting pool contract went to a sleazy Trump donor with a history of bribery and illegal loans. https://t.co/Ot5bJ4In4L https://t.co/hCDidnCC97" / X (10) The Last American Vagabond on X: "https://t.co/x99zqRZZyH" / X (10) The Last American Vagabond on X: "I don't think the team thought this one through. #GrandTheftAmerica" / X New Tab (12) The Last American Vagabond on X: "Trump's CDC just handed Pfizer over $1.2B for new COVID shots. Infant + adult. The big pharma machine never stopped. Full Segment: https://t.co/dLnl9a7jT6 Video by @JasonBassler1 https://t.co/uAvHoGjxSW" / X (12) Derrick Broze on X: "Is this MAHA? Moderna's MRNA Flu Vaccine Backed by FDA Advisers Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's flu vaccine for adults aged 50 and older. https://t.co/Uflt8rcSpM" / X Moderna's MRNA Flu Vaccine Backed by FDA Advisers Trial Details Vaccines and Related Biological Products Advisory Committee June 18, 2026 Meeting Briefing Document- FDA Vaccines and Related Biological Products Advisory Committee June 18, 2026 Meeting Briefing Document- FDA Israel's Election Manipulation Ignored, Over $1B To Pfizer For New COVID Shots & Trump's Iran Lies (12) Mary Talley Bowden MD on X: "This account was just suspended on @X for calling Pfizer a liar?" / X New Tab Trump's "Iran Deal" Is A Veiled Surrender and Retreat For The United States Trump declares Iran is 'FINISHED' amid reports Strait of Hormuz is closed again (15) The White House on X: "Iran is FINISHED. https://t.co/V9AXJ3VtTb" / X (15) RT on X: "DEPARTMENT OF WAR: ‘Give the enemy NIGHTMARES' COMMUNITY NOTE: ‘They gave the enemy $300 Billion instead' https://t.co/96q9utumkW https://t.co/tXAsb1Lvtb" / X (15) Seyed Mohammad Marandi on X: "The Zionists are massacring Lebanese families, while Trump confirms he'll keep Iran's frozen assets hostage. The Islamic Republic has proven that the Epstein Coalition is deceptive and untrustworthy. Their murderous and reckless policies will soon bring down the global economy. https://t.co/wQptsXR3i2" / X (15) Acyn on X: "Caputo: You had talked about you only wanted unconditional surrender. The MOU doesn't look like unconditional surrender. Trump: Well, it really probably is unconditional surrender. Caputo: It is? Trump: I think so. https://t.co/A3JENjaXES" / X (19) The Last American Vagabond on X: "This is just sad. You always know it's an obvious win, when they have to walk you through WHY it's a win, let alone use abstract and undefinable claims as reference points, and use achievements that were the status quo before the war was started. #WINNING" / X New Tab (19) The Kobeissi Letter on X: "BREAKING: Iran officially posts the fully executed “Memorandum of Understanding” which has now taken effect. https://t.co/LteFvqqL9v" / X U.S.-Iran deal: Read the full text (19) Aaron Rupar on X: "Q: They are being allowed to sell oil without making concrete nuclear commitments. How is that not lopsided? JD VANCE: They've made very concrete nuclear commitments. They have committed to the destruction of their highly enriched stockpile. https://t.co/vsJ3ZVeAt9" / X (19) Ryan Rozbiani on X: "I just realized, almost EVERYTHING the Iranian negotiation team told us about this deal from the first day of the ceasefire turned out TRUE Everything Trump told us he would do, he CONCEDED on. Iran even gets to KEEP their Nuclear Program for civilian purposed. Even TRUMP https://t.co/BPt49yC4R5" / X New Tab (19) Ambassador Mike Huckabee on X: "Fortunately @SecRubio made clear that Iran & Hezbollah aren't linked in a deal. @Israel doesn't need Iran permission to defend itself. The tether of terror must end." / X (19) The White House on X: ""The United States is committed to PEACE... We expect a complete Ceasefire on all fronts, including Lebanon, Hezbollah, and Israel." - President Donald J. Trump

Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/el-mananero-radio--3086101/support.

It's been one year since the U.S. Centers for Disease Control and Prevention, in an unprecedented move, dismissed all the members of its Advisory Committee on Immunization Practices (ACIP), kicking off what would turn out to be a very concerning and busy year for infectious disease specialists.  We're going to recap this turbulent period – which includes a resurgence of measles, an unusually rough flu season, the emergence of a new COVID strain and outbreaks of hantavirus and Ebola – with Dr. William Schaffner, one of the country's most frequently quoted medical experts on infectious disease, vaccination, and public health. As a member of ACIP for decades, Dr. Schaffner brings unique insight into the dismantling of the committee and the distrust of vaccines that lies at the root of the changes. As he explains to Raise the Line host Lindsey Smith, while many vaccine critics are beyond reach, there are those he describes as vaccine hesitant that may be persuadable if the right approach is taken. “Beyond providing facts, we have to listen to them and respond to their concerns and make them feel comfortable. Information is fundamental, but behavior change only comes with a change in attitude.” Tune in for a wealth of wisdom and context that includes observations on: What's complicating containment of the Ebola outbreak; Challenges in public health communication in the current social media environment; What grade health authorities should get on their response to the hantavirus outbreak. Mentioned in this episode:Vanderbilt University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this interview I talked with the Senator from Wisconsin, Ron Johnson. We discussed his bombshell report called, Unmasked: How Biden Health Officials Purposely Turned a Blind Eye Toward COVID-19 Vaccine Safety Signals. In this report, Senator Johnson and his team reveals that many people within the FDA and HHS, among other governmental organizations, knew that the COVID-19 vaccines were linked to strokes and even death as early as 2021. Senator Johnson's team found conclusive evidence that the United States Government, the majority of American media companies, and the monopolistic Pharmaceutical Companies worked together to suppress the truth about the Vaccines and, in turn, killed thousands of innocent American citizens. For being one of the most significant reports in modern history, you would think that this story would be on the front page of every major news network and newspaper in America – you would be wrong. Senator Johnson sent his own Op-Ed regarding this report to The New York Times, The Wall Street Journal, USA Today, and many other publications and, to nobodies surprise, he was turned down for publication. We think this had something to do with the fact that many, if not all, of these news companies are sponsored by Pfizer or Moderna and would rather keep in good standing with their financiers than tell the American people the truth about what happened during the COVID-19 Pandemic. We, at The Paradox Press, are not beholden to the Medical Mafia and for that reason, we have the ability to tell the truth. I hope you enjoy. BUY DR MARY TALLEY BOWDEN'S BOOK Go subscribe to The Paradox Press now!Follow me on X: https://x.com/andyschmitt99

In der heutigen Folge sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über Zweifel am Debasement Trade, die große Biontech-Debatte, und die Hausse des Gebrauchtwagenhändlers Auto1. Außerdem geht es um SpaceX, Moderna, BioNTech, AMD, Arm, Broadcom, Intel, Micron, Apple, Auto1, Kroger, BMW, Volkswagen, Mercedes-Benz, Tesla, BYD, SAIC, Commerzbank, Goldman Sachs. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

In der heutigen Folge sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über die Angst der Börsenbosse, Snaps möglichen 2200-Dollar-Brillenflop und die Eskalation der Übernahmeschlacht um Deutschlands zweitgrößte Bank. Außerdem geht es um SpaceX, Amazon, Microsoft, Mercedes-Benz Group, Porsche AG, Volkswagen, GEA Group, Deutsche Bank, SFC Energy, Moderna, Yum Brands, Cboe Global Markets, Miami International Holdings, CME Group, Nasdaq, Hyperliquid Strategies, Meta Platforms, Alphabet, Warby Parker, Apple, UniCredit, Goldman Sachs, Infineon, ASML, Siemens, Rolls-Royce, Enel, Schneider Electric, ABB, Iberdrola, Siemens Energy, ASM International, Prysmian, BE Semiconductor Industries, VAT Group, Aixtron, Soitec, SÜSS MicroTec, Siltronic, Legrand, Nexans, NKT, Engie, National Grid, RWE, E.on, SSE, Terna, Elia. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

A new Wash U Medicine study takes a closer look at an investigational mRNA-based flu vaccine from Moderna that appears to protect against a wide array of influenza strains. KMOX Health Editor Fred Bodimer found out more about that when he talked with one of the authors of the study Wash U Medicine immunologist Dr. Hanover Matz

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

Sabemos la responsabilidad que implica traer un hijo al mundo, o tal vez hacerse cargo de una mascota. Por eso las parejas modernas están optando por no tener responsabilidades y gastarse su dinero en viajes y placer. Mantente al día con los últimos de 'El Bueno, la Mala y el Feo'. ¡Suscríbete para no perderte ningún episodio!Ayúdanos a crecer dejándonos un review ¡Tu opinión es muy importante para nosotros!¿Conoces a alguien que amaría este episodio? ¡Compárteselo por WhatsApp, por texto, por Facebook, y ayúdanos a correr la voz!Escúchanos en Uforia App, Apple Podcasts, Spotify, y el canal de YouTube de Uforia Podcasts, o donde sea que escuchas tus podcasts.'El Bueno, la Mala y el Feo' es un podcast de Uforia Podcasts, la plataforma de audio de TelevisaUnivision.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In 2011, Stéphane Bancel walked away from the security of leading a 6,000-person diagnostics company to join a startup of about 50 people, built on an idea most scientists had dismissed: that messenger RNA could become medicine. Almost everyone told him not to do it. He gave the bet roughly a five percent chance. Nine years later, that same bet helped the world face a pandemic in 63 days.Stéphane Bancel is the Chief Executive Officer of Moderna. Under his leadership the company designed a COVID-19 vaccine on a computer within days of the genetic sequence being posted, delivered the first dose to a human just 63 days later, and scaled from zero manufacturing to a billion doses in twelve months. Today Moderna is building personalized cancer vaccines and using AI to reinvent how medicines are discovered and made.This conversation sits right at the heart of what I believe about leadership. That the chief executive is really the chief energy officer. That the boldest decisions are rarely about appetite for risk, they are about the asymmetry between what you could give the world and what you could actually lose. Stéphane lives both, and he is refreshingly honest about the storms, the doubts and the mistakes along the way.In our conversation, we explore: → The five percent bet: how he weighed an enormous upside against a manageable downside, and why his wife was the only one who said yes → What sailing without GPS taught him about staying calm when the storm hits, and why a storm always passes → The 63-day sprint, and the Sunday phone call that saved the manufacturing of a billion doses → Why he slowed a trial down so it would be a vaccine for the world, not a vaccine for white people → The future he sees: personalized cancer vaccines, the human body mapped in silico, and why he calls chemotherapy tomorrow's barbaric history“I still believe that we have not invented yet our best drug.” Stéphane Bancel, CEO of ModernaIf you have ever faced a decision that everyone around you called too risky, this one is about how to think, and how to stay calm, when you choose to leap anyway.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about the death of Bulls legend Stacey King, a new study that shows flu medications have the potential to reduce cognitive decline as well as premature aging in people living with HIV, and an experimental vaccine from Moderna […]

As health workers in the Democratic Republic of Congo (DRC) continue to battle an ongoing Ebola outbreak, scientists around the world are racing to develop a vaccine against the strain of the virus that's causing it.Two approved vaccines exist for Ebola, but they target the Zaire strain of the virus, not the Bundibugyo strain causing the 2026 outbreak, which has so far killed 61 people with 359 confirmed cases in the DRC and neighbouring Uganda.In this episode, we speak to two scientists at the Oxford Vaccine Group at the University of Oxford, Teresa Lambe and Rebecca Makinson, who are developing a vaccine candidate for Bundibugyo virus. On June 1, they were among three research groups to receive fast-track funding from the Coalition for Epidemic Preparedness Innovations, alongside Moderna and IAVI.This episode was written and produced by Gemma Ware, Katie Flood and Mend Mariwany. Mixing by Eleanor Brezzi and theme music by Neeta Sarl. Read the full credits for this episode and sign up here for a free daily newsletter from The Conversation.If you like the show, please consider donating to The Conversation, an independent, not-for-profit news organisation.

As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career.  “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.”    He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.”  Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Boletín de noticias 04/06/26: Una pareja de ancianos lucha por su vida tras un violento asalto a su domicilio en NSW. Israel y Líbano alcanzan un nuevo acuerdo de alto el fuego. Cuba suspende las transacciones con Visa y Mastercard.

Send us Fan MailIn this fast-paced episode of Neo News, Eli and Ben tackle the rapidly shifting landscape of vaccine regulation and economics in the US. They discuss recent political maneuvers surrounding the Vaccine Injury Compensation Program (VICP) and how expanding liability could quietly push manufacturers out of the market entirely. The hosts also examine the FDA's recent hesitation to review Moderna's new mRNA flu vaccine, highlighting how these administrative roadblocks threaten the financial viability of developing novel vaccines—including critical immunizations for pediatric and neonatal populations. Tune in for a sharp analysis of how top-down policy changes might reshape everyday clinical practice!----1) https://thehill.com/policy/healthcare/5689850-kennedy-dismisses-vaccine-advisors/2) https://www.washingtonpost.com/opinions/2026/01/15/rfk-jr-vaccines-autism-vicp/3) https://www.nytimes.com/2026/02/18/health/fda-moderna-flu-vaccine-mrna.html4) https://www.nytimes.com/2026/02/16/health/rfk-vaccine-manufacturers.htmlSupport the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

The media is working overtime to manufacture the next viral panic, and pharma companies are making big money from the fear campaign. After confirming they were already working on a Hantavirus mRNA vaccine before the cruise ship outbreak – and also developing mRNA vax for ebola – Moderna's stock jumped 20%. What an odd coincidence… Diagnostic pathologist Dr. Clare Craig joins Dr. Drew to expose the suspicious timing behind the latest virus hysteria and what the pharmaceutical industry might be planning next – monkeypox, ebola, bird flu, or worse. Eric Bolling breaks down the economic warning signs flashing across the country as diesel prices near all-time highs. CA Lt. Gov. candidate Gloria Romero (running with Steve Hilton) exposes a new plot by California Democrats to repeal the “Top 2” primary system and change the rules of the election to maintain power. Dr. Clare Craig, BM BCh FRCPath, is a Diagnostic Pathologist and author of “Expired: Covid the Untold Story.” She practiced in the NHS for 15 years and became a Fellow of the Royal College of Pathologists. She was the day-to-day pathology lead for the cancer arm of the 100,000 Genomes Project and led R&D at Genomics England. She is Co-Chair of the Health Advisory and Recovery Team (HART Group). Follow at https://x.com/ClareCraigPath Eric Bolling is a TV personality, political commentator, and author. He is the host of TheEDGE and a former co-host of Fox News' The Five. A former commodities trader at the New York Mercantile Exchange specializing in crude oil, gold, and agricultural commodities, he also served on the NYMEX Board of Directors. He is a 2-time NYT bestselling author. Follow at https://x.com/ericbolling Gloria Romero is a candidate for California Lieutenant Governor, running alongside Steve Hilton. A former California State Senate Majority Leader, she was elected to the State Assembly in 1998 and the Senate in 2001. She left the Democratic Party in September 2024 and joined the Republican Party. She is also a professor, educator, and businesswoman. Learn more at https://gloriaromero.com 「 SUPPORT OUR SPONSORS 」 • COVEPURE – Do you know what's in your tap water? Get $250 off your purifier at https://covepure.com/DREW ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

A Dutch couple goes "bird watching" at a landfill in Argentina. Days later, they board a cruise ship — and a Hantavirus outbreak that hadn't surfaced in years suddenly spreads across the passengers. Now Americans from that ship are quarantined in landlocked Nebraska, Moderna's stock has jumped 7.5% on a Hantavirus vaccine they were already developing, and the WHO wants $300 million back from the United States. Does any of this actually add up? Lance Wallnau breaks down the Hantavirus story the mainstream headlines won't touch — what's real, what's suspicious, and what every Christian needs to know before the next pandemic playbook gets rolled out. Bird watching at a landfill? Seriously?   In this episode:   The Argentina landfill detail that government investigators will only speak about anonymously Why Moderna's stock jumped 7.5% on a Hantavirus vaccine BEFORE the outbreak hit headlines The Wuhan wet-market parallel hiding inside the Patagonia origin story Why the WHO wants $300 million back from the U.S. — and why Trump is saying no What Dr. Peter McCullough is recommending Americans keep on hand right now The prophetic prayer over the outbreak — and why Lance believes this one dissipates A Dr. Ben Carson exclusive on the 1963 communist memo that predicted today's headlines America's 250th anniversary, the rededication on the 17th, and why young men are returning to faith in droves   This is the briefing the WHO doesn't want you watching — and the one every believer needs before the next news cycle hits.   Podcast Episode 2118: The Hantavirus 'Bird Watching' Story Nobody Actually Believes | don't miss this! Listen to more episodes of the Lance Wallnau Show at lancewallnau.com/podcast  

On this, our 325th Evolutionary Lens livestream, we discuss Hanta virus and drought. First: what is the natural history of Hantavirus, do any Hantaviruses transmit directly from human to human, and what is going on with the M.V. Hondius, the cruise ship on which Hantavirus has made a stand? Given its mechanisms of action, Ivermectin is likely to treat Hantavirus (a negative sense single-stranded RNA virus), but the WHO dismisses the possibility. Moderna is working on a Hantavirus vaccine, even though the Number Needed to Treat is sky high. What is going on? Then: in Washington state, we're experiencing a very wet drought. The Department of Ecology has declared a drought (again), and the snow pack is low, but all other indicators—from rivers to reservoirs to soil moisture—are excellent. Cliff Mass, atmospheric scientist, puts the evidence in one place and calls bull on the drought diagnosis.*****Our sponsors:Xlear: Xylitol nasal spray that acts as prophylaxis against respiratory illnesses by reducing the stickiness of bacteria and viruses. Find Xlear online, or at your local pharmacy, grocery store, or natural products store.Fresh Pressed Olive Oil Club: Freshly harvested and delicious. Go to http://www.GetFreshDarkHorse.com to get a bottle of the best olive oil you've ever had for $1 shipping.CrowdHealth: Pay for healthcare with crowdfunding instead of insurance. It's way better. Use code DarkHorse at http://JoinCrowdHealth.com to get 1st 3 months for $99/month.*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org*****Mentioned in this episode:Hantavirus and the elders: https://asm.org/articles/2024/october/indigenous-knowledge-solved-mysterious-outbreakToledo et al 2022. Evidence for human-to-human transmission of hantavirus: a systematic review. The Journal of infectious diseases, 226(8): 1362-1371: https://academic.oup.com/jid/article/226/8/1362/6369311Zaidi & Dehgani-Mobaraki 2022. The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review. The Journal of antibiotics, 75(2): 60-71: https://www.nature.com/articles/s41429-021-00491-6The WHO on the recent outbreak: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON599Cliff Mass – There is no drought emergency: https://cliffmass.blogspot.com/2026/05/the-is-no-drought-emergency-in.htmlStatewide drought declared in WA: https://ecology.wa.gov/about-us/who-we-are/news/2026/april-8-statewide-drought-declared-due-to-dismal-snowpackSupport the show